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The presence of neurofibrillary tangles (NFTs) is a hallmark feature of various neurodegenerative disor-
ders including Alzheimer’s (AD) and Niemann-Pick type C (NPC) diseases. NFTs have been correlated with
elevated cholesterol levels and a cholesterol-scavenging compound, cyclodextrin, effectively modulates
and traffics cholesterol from cell bodies in NPC disease models. Cyclodextrins are also used as drug car-
riers to the blood–brain barrier (BBB) and other tissues. While cyclodextrins have potential value in treat-
ing brain diseases, it is important to determine how cyclodextrins affect natively unfolded proteins such
as beta-amyloid (Ab) whose aggregation has been correlated with AD. We show that cyclodextrins dras-
tically alter Ab aggregation kinetics and induce morphological changes to Ab that can enhance toxicity
towards SH-SY5Y human neuroblastoma cells. These results suggest that care must be taken when using
cyclodextrins for BBB delivery or for treatment of brain disease because cyclodextrins can promote toxic
aggregation of Ab.
 2009 Elsevier Inc. All rights reserved.Delivery of therapeutic agents to the brain is a significant prob-
lem for treating a wide variety of brain diseases due to the diffi-
culty in getting the agents across the tightly regulated blood–
brain barrier (BBB). The endothelial cells of the BBB form a tight
junction that prevents many toxic chemicals from entering the
brain [1–3]. To facilitate delivery of therapeutics to the brain, com-
pounds such as cyclodextrins that can increase membrane perme-
ability have been utilized as delivery vehicles [3–6]. Cyclodextrins
are cyclic oligosaccharides that contain a lipophilic core and hydro-
philic outer surface. The solubility of hydrophobic drugs can also
be enhanced by complexing the drug with the lipophilic core of
cyclodextrins [7,8]. A cyclodextrin/drug complex increases both
the drug bioavailability and also improves drug absorption across
the membrane by extracting cholesterol, phospholipids and pro-
teins to increase membrane permeability [4,5,7,8].
In addition to use as drug delivery vehicle, cyclodextrins have
also been studied as potential therapeutics for various diseases
such as Niemann-Pick type C (NPC) disease and Gaucher disease
[9,10]. NPC disease is a form of progressive neurodegenerative dis-
order characterized by the intracellular accumulation of choles-
terol due to the lack of functional NPC1 protein in the cells [9],
while Gaucher disease is a lysosomal storage disorder affecting
the liver, spleen bone marrow and brain [10]. Cyclodextrins canll rights reserved.
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enabling them to bind and traffic cholesterol away from cell bodies
[9,11]. Because of this capability, a derivative of b-cyclodextrin
known as 2-hydroxypropyl-b-cyclodextrin (HP-b-CD) has recently
been approved by the food and drug administration (FDA) for the
treatment of NPC disease [12]. Treatment with HP-b-CD was
shown to be effective in delaying neurological symptoms of NPC
[2] and administration of HP-b-CD successfully transported choles-
terol away from cell bodies animal model studies [11,13]. Promis-
ing results from the long-term clinical trials paved the way for the
FDA’s approval of the compassionate use of cyclodextrins in treat-
ing NPC disease [14].
Methyl-b-cyclodextrin (M-b-CD), another derivative of b-cylod-
extrin, was shown to lower cholesterol levels in transgenic a-syn-
ucleinopathy mice and in cells overexpressing a-synuclein (aS),
resulting in a decrease in oligomeric aS accumulation in vivo,
which was concluded to reduce the risk of Parkinsonism [15].
Interestingly, an elevated level of cholesterol is also a risk factor
for Alzheimer’s disease (AD), and regulation of cholesterol levels
in AD cell model using M-b-CD decreased amyloid precursor pro-
tein processing, essentially inhibited beta-amyloid (Ab) formation,
thereby suggesting a link between cholesterol metabolism and Ab
production [16].
AD affects 4.5 million Americans and over 26 million worldwide
[17] and is characterized by the extracellular deposition of amyloid
plaques and intracellular accumulation of neurofibrillary tangles
(NFTs) in the brain [18]. NFTs are pathological aggregates of hyper-
phosphorylated tau protein [19] and characteristics of tauopathies
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(PSP) [21] and dementia with Lewy bodies (DLB) [22]. Many stud-
ies have focused on the role of Ab in the pathogenesis and progres-
sion of AD [23,24]. While initial in vitro and in vivo studies
indicated that fibrillar Ab could cause neuronal cell death either di-
rectly or by triggering apoptosis [25,26], recent studies suggest
that smaller soluble oligomeric forms of Ab are the relevant cyto-
toxic species [26–28]. A variety of anti-Ab therapeutic agents have
been studied as a therapeutic approach for treating AD including
polyphenols [29] and other small molecules [30].
Natively unfolded proteins such as Ab contain hydrophobic re-
gions that may interact with the hydrophobic core of cyclodextrins,
facilitating accumulation and aggregation of these proteins. Since
cyclodextrins have been approved by the FDA for treatment of
NPC disease, and can lower cholesterol levels which are beneficial
for treating numerous neurodegenerative diseases including AD
and PD, it is important to determine whether cyclodextrins also af-
fect aggregation of neuronal proteins such as Ab. Here we show
that aggregation and cytotoxicity of Ab are altered by several
cyclodextrin derivatives that have been previously studied for
NPC disease treatment [2,9] and for BBB transport applications
[8]: a-, b-, and 2-hydroxypropyl-b-cyclodextrin (a-CD, b-CD and
HP-b-CD, respectively).Materials and methods
Ab peptides. Ab40 was synthesized in the Proteomics and Pro-
tein Chemistry Lab at Arizona State University. Lyophilized Ab
was dissolved in DI water at stock concentrations of 5 mg/mL
and stored at 20 C until use.
Cyclodextrin. a-, b-, and 2-hydroxypropyl-b-cyclodextrins (a-
CD, b-CD and HP-b-CD, respectively) were purchased from Sig-
ma–Aldrich (Sigma–Aldrich, MO) and stocks were prepared in 1
PBS buffer (10 mM Na2HPO4, 2 mM KH2PO4, 140 mM NaCl, and
2.7 mM KCl, pH 7.4) and stored at room temperature until use.
In vitro Ab aggregation. Ab stock was sonicated for 15 min before
use and was diluted to a concentration of 50 lM in 1 PBS (pH
7.4). Cyclodextrins were dissolved in 1 PBS to concentrations of
20 mM and 200 mM, respectively. Because of the poor solubility
of b-cyclodextrin in aqueous solution, only the lower b-CD concen-
tration (20 mM) was used. The final concentration of Ab was 25 lM
and of each cyclodextrins was either 10 mM or 100 mM. Next, an
equivolume of each cyclodextrin was added to a 50 lM Ab sample
and incubated at 37 C without shaking for 21 days. A control sam-
ple containing Ab with an equal volume of 1 PBS was carried out
in parallel. Aliquots were removed at selected time points through-
out the 21-day incubation period for analysis.
Thioflavin T (ThT) fluorescence. Aggregation of Ab with or with-
out cyclodextrin was monitored using ThT fluorescence intensity
at various time points throughout the 21-day incubation period
as previously described [31]. The maximum fluorescence intensity
value obtained with the Ab alone sample was set to 100 (A.U.) and
subsequent fluorescence intensities of all other samples were nor-
malized to this value.
Atomic force microscopy. The morphology of Ab at different incu-
bation periods over a 21-day time course was evaluated using a
Nanoscope IIIa AFM (Veeco, Santa Barbara, CA). A 5 lL aliquot from
each incubated sample was deposited on a piece of freshly cleaved
mica for 5 min, rinsed with DI water, dried with N2 gas and imaged
with AFM. OTESPA AFM tips (Veeco, Santa Barbara, CA) were used
for AFM imaging using a scan rate of 2.5 Hz and 512 pixels resolu-
tion. Images were subjected to 2nd or 3rd order polynomial flat-
tening as needed to reduce the effects of bowing and tilt.
Representative images were selected for comparative studies.Cell culture. SH-SY5Y human neuroblastoma cells were main-
tained and grown as previously described [31].
Cytotoxicity assay. The cytotoxicity of each sample towards SH-
SY5Y cells was measured using a lactate dehydrogenase (LDH) as-
say as described elsewhere [32]. Reduction of p-iodonitrotetrazoli-
um by LDH enzyme was measured at 490 nm and 650 nm using a
Wallac 1420 plate reader (Perkin Elmer, USA). Cytotoxicity of each
sample was calculated by subtracting A490 from A650, normalized to
the control (Ab alone) and expressed as a percentage of the control
value. Experiments were repeated in triplicate.
Cell viability assay. Cell viability was determined using a resazu-
rin reduction assay [33,34]. Following treatment for 48 h, culture
media was removed and replaced with 1 PBS and resaruzin
(20 lM final concentration) was added to each well and incubated
at 37 C for 2 h. Fluorescence of resofurin was measured using a
Gen5 BioTek plate reader at excitation and emission wavelengths
of 530 nm and 560 nm, respectively. Cell viability of each sample
was normalized to that of the PBS control. Experiments were re-
peated in triplicate.
Data and statistical analysis. Data was presented as mean ± SE
from at least three independent experiments unless otherwise
specified. Cytotoxicity and cell viability data were fitted to a lin-
ear-log logistics dose-response curve [35] to determine LD50 values
for each sample. Statistical analysis was performed using a two-tail
Student’s t-test with the PBS treated samples being the control. A
p-value of <0.05 was considered significant.Results and discussion
Cyclodextrin effects on Ab aggregation
We monitored how the different cyclodextrins influence fibril-
lar Ab aggregation using ThT fluorescence (Fig. 1). In the absence
of cyclodextrins, Ab aggregation follows a classical nucleation
polymerization mechanism with three distinct phases: nucleation
(0–7 days), elongation (7–10 days) and a plateau phase where fibril
formation reaches steady state (>10 days). Co-incubation with
10 mM of either b-CD or HP-b-CD accelerates Ab fibril formation,
reducing the time to reach the maximum ThT fluorescence value
from 10 to 5 days. Unlike the Ab alone sample, the ThT fluores-
cence value of Ab co-incubated with cyclodextrins decreases after
reaching a maximum value, indicating a decrease in fibrillar b-
sheet contents (Fig. 1). Co-incubation of Ab with 100 mM a-CD
completely inhibits Ab fibril formation, as determined by ThT fluo-
rescence (Fig. 1). The cyclodextrins alone did not alter the ThT fluo-
rescence signal.
ThT results suggest that Ab aggregation is differentially affected
by cyclodextrins depending on characteristics which may include
cavity size, concentration, surface charge, hydration forces and
hydrophobicity of the cyclodextrins. The 7-glycopyranose unit b-
CDs (b-CD and HP-b-CD) promote Ab fibrillogenesis at the lower
concentrations studied but inhibit fibrillogenesis at the higher con-
centrations. The smaller 6-glycopyranose unit a-CD decreases Ab
fibrillogenesis at the low concentration and completely inhibits it
at the higher concentrations compared to Ab alone. Previous stud-
ies indicate that polyols and sugars can stabilize protein structures
by forming hydrogen bonds with water molecules and preferen-
tially allowing water to be excluded from the hydrophobic surfaces
[36]. Since Ab is natively unfolded, the cyclodextrins studied here
may facilitate association of hydrophobic surfaces between differ-
ent Ab proteins promoting aggregation to oligomeric and fibrillar
aggregates. Since the aggregation state of Ab determines its cyto-









0 4 8 12 16 20 24
time (days)













































Fig. 1. Effects of cyclodextrins on Ab aggregation. Ab aggregation with 10 mM (A) or
100 mM (B) of each cyclodextrin was monitored using ThT fluorescence assay. Ab
alone (d), Ab + a-CD (N), Ab + b-CD () and Ab + HP-b-CD (h). The observed
fluorescence was normalized Ab alone sample at its maximum value. Data are
presented as mean ± SE from four sets of experiments.
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We assessed the effects of the different cyclodextrins on Ab
morphology by AFM (Fig. 2). Since the cyclodextrins alter the rate
of Ab aggregation, we compared morphologies of Ab aliquots based
on respective maximum ThT values rather than corresponding
time points. The AFM images show that co-incubation of Ab with
different cyclodextrins induces substantial morphological changes
in Ab structure compared to the Ab alone sample (Fig. 2A). For
example, co-incubation of Ab with a-CD promotes formation of
large oligomeric Ab species (Fig. 2B and C), b-CD promotes forma-
tion of short, thick Ab fibrils and HP-b-CD promotes formation of
fibrils similar to those generated by Ab alone though substantially
shorter (Fig. 2D–F). We also studied how Ab morphology changes
throughout the 21-day time course with and without co-incuba-
tion with cyclodextrins. Time course AFM images of Ab alone and
Ab + 10 mM b-CD are shown in Fig. 3 and all others are shown in
the Supplementary material. When incubated alone, Ab fibrillogen-
esis followed a typical seeded-nucleation aggregation kinetics, pro-
ceeding from oligomers to protofibrils and fibrils, as indicated by
ThT fluorescence and AFM image (Fig. 1B and A). Co-incubation
with 10 mM b-CD showed considerable oligomeric formation in
3 days and extensive fibril formation after just 5 days. The fibrils
remained through the 21-day incubation period (Fig. 3B). The pres-
ence of Ab fibrils did not correspond with the ThT value (Fig. 1B),
suggesting that either the fibrils are not typical b-sheet stackedstructures or that the ThT fluorescence staining of the fibrils is
shielded by the HP-b-CD. In either case, cyclodextrins clearly alter
Ab aggregation, promoting formation of small spherical oligomers,
protofibrils, short rigid and short intertwining fibrils. Since Ab mor-
phology greatly influences its cytotoxic characteristics, we studied
how the different Ab aliquots affect cell viability.
Co-incubation of Ab with cyclodextrins affects cell viability
The connection between the aggregation state of Ab and cyto-
toxicity has been widely studied [25,27]. Increasing evidence sug-
gests that small soluble oligomeric Ab species are the relevant
neurotoxic species in AD [27,28]. Therefore, we determined the
toxicity of the various Ab-CD induced aggregates using the neuro-
blastoma cell line, SH-SY5Y. The baseline toxicity of each cyclodex-
trin on SH-SY5Y cells was determined and b-CD was the most toxic
followed by a-CD and HP-b-CD with LD50 values of 2 mM, 11 mM
and 147 mM, respectively in a cell culture density of 105 cells in a
24-well plate (data not shown). LD50 values are all well above the
concentrations used in Ab toxicity studies, indicating the cyclodex-
trins alone do not induce toxicity. When aggregated without added
cyclodextrins, Ab induced a significant decrease in cell viability
after aggregation for 3 and 5 days, respectively, but was not toxic
to cells at earlier and later aggregation time points (Fig. 4), consis-
tent with other studies indicating toxicity of oligomeric but not
monomeric or fibrillar Ab [27,28]. When incubated with 10 mM
a-CD, Ab induced significant toxicity towards SH-SY5Y cells at
10 days and longer time points (Fig. 4A). At the higher concentra-
tion of a-CD (100 mM), Ab-induced toxicity was observed at earlier
time points (Fig. 4B). No toxicity was observed at the studied time
points when Ab was co-incubated with 10 mM HP-b-CD, although
a significant decrease in cell viability was observed when Ab was
co-incubated with 100 mM HP-b-CD for 5 days or longer
(Fig. 4B). Co-incubation of Ab with 10 mM b-CD did not affect cell
viability at the low concentration for the time points studied here
(Fig. 4A), and the higher concentration studies could not be per-
formed due to the poor solubility of b-CD in aqueous solutions.
While cyclodextrins hold great therapeutic promise as drug
delivery vehicle and for regulating cholesterol levels, their lipo-
philic core can alter aggregation of natively unfolded proteins such
as Ab. Since the aggregation states of Ab is crucial for cytotoxicity,
it is critically important to determine how cyclodextrins affects Ab
protein aggregation. Here we show that different cyclodextrins
influence Ab aggregation and promote formation of oligomeric
and fibrillar species. Based on AFM and ThT studies, a-CD promotes
formation of oligomeric Ab species, which is reflected in the in-
creased cytotoxicity observed with the a-CD co-incubated sam-
ples. The two different b-CD variants both promote formation of
short fibrillar Ab aggregates at low concentration (10 mM), how-
ever at the higher concentration (100 mM) HP-b-CD also stabilizes
oligomeric Ab aggregates which are toxic to SH-SY5Y cells. While
formation of fibrillar aggregates has been suggested to be a protec-
tive mechanism that can sequester toxic oligomeric species [37],
other studies have shown that promoting fibril formation may also
increase cytotoxicity [38].
Formation of NFTs has been linked to high cholesterol levels in
cells, particularly in lipid rafts on cell membranes. Lipid rafts, com-
prised mainly of cholesterol and sphingolipids can also promote
pathogenesis of AD by serving as a deposition site for the accumu-
lation and aggregation of Ab [16]. Since natively unfolded neuronal
proteins such as Ab and aS are known to associate with lipid rafts
[15,16], and cyclodextrins can interact with cholesterol on lipid
rafts, the local concentrations of cyclodextrins and neuronal pro-
teins on the lipid rafts can be much higher than elsewhere. While
the ability of cyclodextrins to scavenge and traffic cholesterol away
from cells shows great therapeutic promise prompting the FDA to
Fig. 2. AFM images of Ab samples with and without co-incubation with cyclodextrins at maximum ThT fluorescence. Ab alone (A), Ab + 10 mM a-CD (B), Ab + 100 mM a-CD
(C), Ab + 10 mM b-CD (D), Ab + 10 mM HP-b-CD (E) and Ab + 100 mM HP-b-CD (F). AFM imaging was carried out in air using TMAFM. Scale bar = 500 nm.
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dren [12], the potential effects of cyclodextrins on aggregation of
natively unfolded proteins such as Ab, tau and a-synuclein and
the subsequent long-term effects on cell toxicity are not known.
Here we show that cyclodextrins interact with Ab and significantlyFig. 3. Morphological changes of Ab with time as monitored by AFM. Ab alone (A) an
bar = 500 nm.alter the aggregation kinetics, morphology, and toxicity of Ab to-
wards neuronal cells. While cyclodextrins have value as treatments
for NPC disease and Gaucher disease, and as delivery vehicles to
transport drugs to tumors [6] or to cross the BBB [2,8], the concen-
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Fig. 4. Co-incubation of Ab with cyclodextrin affects viability of SH-SY5Y cells. Ab was pre-incubated with 10 mM cyclodextrin (A) or 100 mM cyclodextrin (B) at 37 C for
21 days. Ab co-incubated with Ab alone (h), Ab + a-CD ( ), Ab + b-CD ( ) and Ab + HP-b-CD (j). The pre-incubated Ab samples at each time point from each set were added
to SH-SY5Y cells and incubated at 37 C for 48 h. Cell viability was measured using a resazurin reduction assay and normalized to PBS control. Data were presented as
mean ± SE. *p < 0.05; **p < 0.01 compared with the control.
530 M.S. Wang et al. / Biochemical and Biophysical Research Communications 386 (2009) 526–531and local concentration effects especially around lipid rafts should
be carefully studied to ensure the long-term safety of
cyclodextrins.
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